Recon CollPlant Announces Completion of Patient Recruitment for Clinical Trial of Vergenix™FG (Flowable Gel) for the Treatment of Chronic Wounds byJosh SandbergOctober 8, 2015
Recon CollPlant Names Shomrat Shurtz Senior Director of Business Development byJosh SandbergAugust 1, 2015
Biologics CollPlant Executes Non-binding Term Sheet to Develop and Commercialize a Novel Product for Spinal Fusion and Trauma Indications in Collaboration with Leading US Partner byJosh SandbergJuly 14, 2015
